There is evidence for somatic mutations in the paralogous gene CREBBP that result in impaired histone acetylation and transcription of CREBBP target genes, including glucocorticoid-receptor-responsive genes, which may influence response to therapy and the likelihood of relapse in ALL [6]. This evidence concerns the gene CREBBP and acute lymphoblastic leukemia.